Queen Mary University of London is a public research university in London, England, and a member institution of the federal University of London. It dates back to the foundation of London Hospital Medical College in 1785.

During the past decade, Queen Mary University of London conducted 48 clinical trials. In the 10-year time frame, 48 clinical trials started and 14 clinical trials were completed, i.e. on average, 29.2% percent of trials that started reached the finish line to date. In the past 5 years, 18 clinical trials started and 6 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Queen Mary University of London" #1 sponsor was "Queen Mary University of London" with 28 trials, followed by "Hoffmann-La Roche" with 15 trials sponsored, "Daiichi Sankyo, Inc." with 4 trials sponsored, "Genentech, Inc." with 4 trials sponsored and "Boehringer Ingelheim" with 4 trials sponsored. Other sponsors include 11 different institutions and companies that sponsored additional 18 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Queen Mary University of London" #1 collaborator was "Barts & The London NHS Trust" with 6 trials as a collaborator, "AstraZeneca" with 5 trials as a collaborator, "Daiichi Sankyo Co., Ltd." with 4 trials as a collaborator, "Queen Mary University of London" with 4 trials as a collaborator and "British Heart Foundation" with 3 trials as a collaborator. Other collaborators include 52 different institutions and companies that were collaborators in the rest 51 trials.

According to Clinical.Site data, the most researched conditions in "Queen Mary University of London" are "Breast Cancer" (7 trials), "Hypertension" (6 trials), "Multiple Sclerosis" (4 trials), "Non-Small Cell Lung Cancer" (4 trials) and "Acromegaly" (3 trials). Many other conditions were trialed in "Queen Mary University of London" in a lesser frequency.

Most popular intervention types in "Queen Mary University of London" are "Drug" (40 trials), "Other" (8 trials), "Dietary Supplement" (7 trials), "Device" (6 trials) and "Procedure" (6 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (12 trials), "Placebo" (10 trials), "BI 685509" (2 trials), "Beetroot juice" (2 trials) and "Cabozantinib" (2 trials). Other intervention names were less common.

The vast majority of trials in "Queen Mary University of London" are 61 trials for "All" genders, 8 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Queen Mary University of London". 1 are not yet recruiting, 8 are recruiting, 14 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 30 completed trials in Queen Mary University of London, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Queen Mary University of London, 8 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 7 trials, and there were also 14 trials that are defined as “Not Applicable".

Queen Mary University of London has several departments that took part in Clinical trials: "Institute of Psychiatry and Neurology" - 10 trials, "Centre for Oral Clinical Research" - 4 trials, "Tobacco Dependence Research Unit" - 4 trials, "Wingate Institute of Neurogastroenterology" - 4 trials, "Centre for Neuroscience & Trauma, Blizard Institute of Cell and Molecular Science, Barts and The London School of Medicine and Dentistry" - 2 trials, "William Harvey Heart Centre" - 2 trials, "NIHR Barts Cardiovascular Biomedical Research Unit" - 2 trials